Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma (NCT06567314)

🧪 Interventions in This Study

• Ivonescimab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• MD Anderson Cancer Center — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 563-3885

Email: anaing@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cutaneous Squamous Cell Carcinoma

• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer — La Jolla, California
• A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma — Albury, New South Wales
• A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer — Aurora, Colorado
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma — Gilbert, Arizona
• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — Boston, Massachusetts

Explore by condition: All Cutaneous Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.